408 related articles for article (PubMed ID: 29911256)
21. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.
Magerus-Chatinet A; Stolzenberg MC; Loffredo MS; Neven B; Schaffner C; Ducrot N; Arkwright PD; Bader-Meunier B; Barbot J; Blanche S; Casanova JL; Debré M; Ferster A; Fieschi C; Florkin B; Galambrun C; Hermine O; Lambotte O; Solary E; Thomas C; Le Deist F; Picard C; Fischer A; Rieux-Laucat F
Blood; 2009 Mar; 113(13):3027-30. PubMed ID: 19176318
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
23. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
Consonni F; Gambineri E; Favre C
Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
[TBL] [Abstract][Full Text] [Related]
24. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
[TBL] [Abstract][Full Text] [Related]
25. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
[TBL] [Abstract][Full Text] [Related]
26. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
27. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
[TBL] [Abstract][Full Text] [Related]
28. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
[TBL] [Abstract][Full Text] [Related]
29. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
[TBL] [Abstract][Full Text] [Related]
30. Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome.
Rensing-Ehl A; Pannicke U; Zimmermann SY; Lorenz MR; Neven B; Fuchs I; Salzer U; Speckmann C; Strauss A; Maaβ E; Collet B; Enders A; Favier R; Alessi MC; Rieux-Laucat F; Zieger B; Schwarz K; Ehl S
Blood; 2015 Oct; 126(16):1967-9. PubMed ID: 26472737
[No Abstract] [Full Text] [Related]
31. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
Marega LF; Teocchi MA; Dos Santos Vilela MM
Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
[TBL] [Abstract][Full Text] [Related]
32. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
[TBL] [Abstract][Full Text] [Related]
33. Rare splicing defects of FAS underly severe recessive autoimmune lymphoproliferative syndrome.
Agrebi N; Ben-Mustapha I; Matoussi N; Dhouib N; Ben-Ali M; Mekki N; Ben-Ahmed M; Larguèche B; Ben Becher S; Béjaoui M; Barbouche MR
Clin Immunol; 2017 Oct; 183():17-23. PubMed ID: 28668589
[TBL] [Abstract][Full Text] [Related]
34. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
36. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.
Neven B; Magerus-Chatinet A; Florkin B; Gobert D; Lambotte O; De Somer L; Lanzarotti N; Stolzenberg MC; Bader-Meunier B; Aladjidi N; Chantrain C; Bertrand Y; Jeziorski E; Leverger G; Michel G; Suarez F; Oksenhendler E; Hermine O; Blanche S; Picard C; Fischer A; Rieux-Laucat F
Blood; 2011 Nov; 118(18):4798-807. PubMed ID: 21885602
[TBL] [Abstract][Full Text] [Related]
37. Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.
Rensing-Ehl A; Lorenz MR; Führer M; Willenbacher W; Willenbacher E; Sopper S; Abinun M; Maccari ME; König C; Haegele P; Fuchs S; Castro C; Kury P; Pelle O; Klemann C; Heeg M; Thalhammer J; Wegehaupt O; Fischer M; Goldacker S; Schulte B; Biskup S; Chatelain P; Schuster V; Warnatz K; Grimbacher B; Meinhardt A; Holzinger D; Oommen PT; Hinze T; Hebart H; Seeger K; Lehmberg K; Leahy TR; Claviez A; Vieth S; Schilling FH; Fuchs I; Groß M; Rieux-Laucat F; Magerus A; Speckmann C; Schwarz K; Ehl S;
J Allergy Clin Immunol; 2024 Jan; 153(1):297-308.e12. PubMed ID: 37979702
[TBL] [Abstract][Full Text] [Related]
38. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
López-Nevado M; González-Granado LI; Ruiz-García R; Pleguezuelo D; Cabrera-Marante O; Salmón N; Blanco-Lobo P; Domínguez-Pinilla N; Rodríguez-Pena R; Sebastián E; Cruz-Rojo J; Olbrich P; Ruiz-Contreras J; Paz-Artal E; Neth O; Allende LM
Front Immunol; 2021; 12():671755. PubMed ID: 34447369
[TBL] [Abstract][Full Text] [Related]
39. Role of inherited defects decreasing Fas function in autoimmunity.
Dianzani U; Chiocchetti A; Ramenghi U
Life Sci; 2003 May; 72(25):2803-24. PubMed ID: 12697265
[TBL] [Abstract][Full Text] [Related]
40. Understanding the Spectrum of Immune Dysregulation Manifestations in Autoimmune Lymphoproliferative Syndrome and Autoimmune Lymphoproliferative Syndrome-like Disorders.
Failing C; Blase JR; Walkovich K
Rheum Dis Clin North Am; 2023 Nov; 49(4):841-860. PubMed ID: 37821199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
